Iberdomide Pairs With Isatuximab to Rescue MRD-Positive Patients After Transplant (Pharmacy Times) - Sep 24, 2026 - "Of 219 patients who started Isa-Iber maintenance (108 in Arm C, 111 in Arm D), 203 completed the first year of treatment. Fifty-five patients converted from MRD-positive to MRD-negative at the stringent 10⁻⁶ sensitivity threshold during that single year of maintenance...Broken out by arm, MRD-negativity at 10⁻⁶ improved from 40% post-consolidation to 58% after one year of maintenance in the single-ASCT arm and from 32% to 48% in the tandem-ASCT arm. At the more commonly used 10⁻⁵ threshold, rates moved from 67% to 76% (Arm C) and from 62% to 70% (Arm D)....No unexpected toxicity signals emerged, and the profile was consistent across both transplant arms."
P3 data • Multiple Myeloma
|